<DOC>
	<DOCNO>NCT01422434</DOCNO>
	<brief_summary>The purpose study compare efficacy LEO 90105 ointment apply daily Dovonex® ointment apply twice daily Rinderon®-DP ointment apply daily Japanese subject psoriasis vulgaris .</brief_summary>
	<brief_title>LEO 90105 Ointment Japanese Subjects With Psoriasis</brief_title>
	<detailed_description>LEO 90105 ointment contains calcipotriol betamethasone dipropionate . It approve treatment psoriasis 60 centre , include European country , US , China , Korea Taiwan . This trial investigate safety efficacy treatment Japanese subject psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Subjects understood sign write informed consent form prior study related procedure carry . Japanese subject . 20 year age . Either sex . Clinical diagnosis psoriasis vulgaris amenable topical treatment , involve arm and/or trunk and/or leg . A minimum mPASI ( Modified Psoriasis Area Severity Index ) score extent 2 least one body region ( i.e . psoriasis affect least 10 % arm , and/or 10 % trunk , and/or 10 % leg ) . Psoriasis vulgaris trunk/limbs ( exclude psoriasis genitals/skin fold ) 30 % body surface area ( BSA ) . A target lesion minimum 5 cm long axis preferably locate elbow knee , score least 3 redness , thickness scaliness , least 10 total physician 's assessment severity target lesion A physician 's global assessment disease severity psoriasis trunk/limbs mild , moderate , severe severe . Females childbearing potential must negative result urine pregnancy test Day 0 ( Visit 1 ) must agree use adequate method birth control , judge ( sub ) investigator , study . The contraceptive method start adequate amount time pregnancy test , dependent particular method use judge ( sub ) investigator , must continue least 1 week last application study medication . A female defined childbearing potential postmenopausal ( 12 month menses without alternative medical cause ) surgically sterile ( tubal ligation/section , hysterectomy bilateral ovariectomy ) . Systemic use biological treatment potential effect psoriasis vulgaris within follow time period prior randomisation : etanercept , adalimumab , infliximab 3 month ustekinumab 4 month product 3 months/5 halflives ( whichever longer ) . Systemic treatment therapy biological treatment potential effect psoriasis vulgaris ( e.g. , corticosteroid , vitamin D analogue , retinoids , immunosuppressant ciclosporin methotrexate ) within 4 week prior randomisation ( use inhale nasal corticosteroid allow , use systemic antihistamine allow ) . Psoralen plus ultraviolet light A ( PUVA ) therapy , ultraviolet light B ( UVB ) therapy ultraviolet light A ( UVA ) therapy within 4 week prior randomisation . Topical treatment psoriasis area ( ) treat study medication within 2 week prior randomisation ( use emollient allow 2week period , randomisation ) . Topical treatment psoriasis face , genitals skin fold vitamin D analogue ( e.g . calcipotriol , tacalcitol , maxacalcitol ) , potent potent World Health Organisation ( WHO ) group III IV corticosteroid within 2 week prior randomisation . Topical treatment scalp psoriasis vitamin D analogue ( e.g . calcipotriol , tacalcitol , maxacalcitol ) , potent WHO group IV corticosteroid within 2 week prior randomisation . Topical treatment condition psoriasis vitamin D analogue ( e.g . calcipotriol , tacalcitol , maxacalcitol ) , potent potent WHO group III IV corticosteroid within 2 week prior randomisation . Planned initiation , change , concomitant medication may affect psoriasis vulgaris ( e.g. , betablockers , antimalaria drug , lithium Angiotensin Converting Enzyme ( ACE ) inhibitor ) study . Current diagnosis erythrodermic , exfoliative , guttate pustular psoriasis . Patients follow disorder ( ) symptom ( b ) present area ( ) treat study medication : ( ) viral ( e.g. , herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , rosacea , acne vulgaris , atrophic skin , stria atrophicae , ichthyosis , acne rosacea , ulcer , burn , frostbite , wound , ( b ) fragility skin veins.. Other inflammatory skin disease ( e.g. , seborrhoeic dermatitis , contact dermatitis cutaneous mycosis ) may confound evaluation psoriasis vulgaris trunk/limbs . Planned excessive exposure area ( ) treat study medication either natural artificial sunlight ( include tan booth , sun lamp , etc ) study . Known suspect disorder calcium metabolism associate hypercalcaemia , albumincorrected serum calcium reference range sample take Washout/Screening Visit . Known suspect severe renal insufficiency , severe hepatic disorder severe heart disease . Known suspected hypersensitivity component investigational product . Clinical sign symptoms Cushing 's disease Addison 's disease Current participation interventional clinical study . Subjects receive treatment nonmarketed drug substance ( i.e . agent yet make available clinical use follow registration ) within 4 week prior randomisation , long class substance require long washout define exclusion criterion number 1 biological treatment . Females pregnant , wish become pregnant study , breastfeed . Patients suspect unable comply study protocol , e.g . due alcoholism , drug dependence psychotic state . Previous randomisation study . Hospitalised patient .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>A national</keyword>
	<keyword>multi-centre</keyword>
	<keyword>prospective</keyword>
	<keyword>randomise</keyword>
	<keyword>double-blind</keyword>
	<keyword>active-controlled</keyword>
	<keyword>3-arm</keyword>
	<keyword>parallel group</keyword>
	<keyword>4 week study</keyword>
</DOC>